Suit: Amgen underpaid royalties

While Northwestern swims like Scrooge McDuck in its $700 million Lyrica payment, Sloan-Kettering Institute for cancer research is suing Amgen for underpaying royalties by more than $72 million. The cancer center claims that, when calculating royalties, Amgen deducted Aranesp-related rebates from Neupogen and Neulasta sales. The latter two drugs sold at a rate of $1.1 billion just in the third quarter. Amgen denies the claims.

- check out this report
- read the Pharmalot item

Related Articles:
Northwestern sells Lyrica rights for $700M. Report
Lyrica OK'd for epilepsy. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.